세계의 패혈증 진단 시장 : 시장 예측(어세이별, 원인별, 제품별, 랩별, 장소별) - 주요 컨설턴트 가이드 첨부(2025-2029년)

Sepsis Diagnostic Markets. Global Market Forecasts by Assay, by Cause, by Product, by Lab, and by Place. With Executive and Consultant Guides. 2025 - 2029

US $ 6,995 ￦ 10,124,000

PDF (Single User License)

PDF 보고서를 1명(One device)만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 10,495 ￦ 15,190,000

PDF (Five User License)

PDF 보고서를 동일 사업장의 5명(Five devices)까지 이용할 수 있는 라이선스입니다. 인쇄 불가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 13,995 ￦ 20,256,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄는 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

연간 4,500만명 이상이 패혈증을 앓고 있지만, 놀랍게도 결정적인 진단법은 없습니다.

본 보고서는 세계의 패혈증 진단 시장에 대해 조사했으며, 시장 개요와 함께 분석별, 원인별, 제품별, 실험실별, 장소별 동향, 시장 진출기업 프로파일 등의 정보를 제공합니다.

목차

제1장 시장 가이드

제2장 소개와 시장 정의

• 패혈증 진단의 개요
• 시장의 정의
• 조사 방법
• 관점: 헬스케어와 IVD 업계

제3장 패혈증-현재 과학

• 패혈증이란 무엇인가
• 진단
• 패혈증의 원인
• 유병률

제4장 업계 개요

• 시장 진입기관
  • 학술연구기관
  • 진단 시험 개발자
  • 계장 공급자
  • 약품 및 시약 제조업체
  • 병리 공급자
  • 독립계 임상 실험실
  • 공공의 국립/지역 연구소
  • 병원 검사실
  • 임상 실험실
  • 감사기관
  • 인증기관

제5장 시장 동향

• 성장 촉진요인
• 성장 억제요인
• 계측, 자동화, 진단의 동향

제6장 패혈증 진단-최근 동향

제7장 주요 기업 프로파일

• Abbott Laboratories
• Abionic
• Accel Diagnostics
• Accelerate Diagnostics
• ADT Biotech
• Anatolia Geneworks
• Axis-Shield Diagnostics Ltd.
• Baebies
• Beckman Coulter Diagnostics
• Becton, Dickinson and Company
• Biocartis
• BioFire Diagnostics(bioMerieux)
• bioMerieux Diagnostics
• Bio-Rad Laboratories, Inc.
• Bruker
• Cube Dx
• Curetis NV/Curetis GmbH
• Cytovale
• Deepull Diagnostics
• DNAe
• EKF Diagnostics Holdings
• GeneFluidics
• GenMark Dx(Roche)
• Grifols
• Immunexpress
• Inflammatix
• LightDeck Diagnostics
• Linear Diagnostics
• Luminex Corp(DiaSorin)
• Mobidiag(Hologic)
• NanoDx
• Nanomix
• Qiagen
• Response Biomedical
• Roche Molecular Diagnostics
• SeLux Diagnostics
• Septec
• Siemens Healthineers
• Sphingotec
• T2 Biosystems
• Thermo Fisher Scientific Inc.
• Vela Diagnostics

제8장 세계의 패혈증 진단 시장 개요

• 세계의 패혈증 진단 시장 개요(국가별)
• 세계의 패혈증 진단 시장 개요(어세이별)
• 세계의 패혈증 진단 시장 개요(원인별)
• 세계의 패혈증 진단 시장 개요(제품별)
• 세계의 패혈증 진단 시장 개요(랩별)
• 세계의 패혈증 진단 시장 개요(장소별)

제9장 패혈증 진단 시장 - 분석별

• 미생물학
• PCR
• 면역 측정
• 감염증 기타
• 바이오마커 분자진단
• 바이오 마커 기타

제10장 세계의 패혈증 진단 시장-원인별

• 위장
• 호흡기계 COVID-19
• 호흡기 기타
• 신생아
• 기타

제11장 세계의 패혈증 진단 시장 - 제품별

• 기기
• 소모품
• 소프트웨어 및 서비스

제12장 세계의 패혈증 진단 시장- 실험실별

• 랩내
• 포인트 오브 케어

제13장 세계의 패혈증 진단 시장-장소별

• 병원
• 기타

제14장 부록

JHS

영문 목차

영문목차

Report Overview:

Over 45 million people a year suffer from sepsis but surprisingly there is no definitive diagnostic. The race is on using all the genomic and molecular diagnostic tools that have come to the fore in the last decade.

Will Artificial Intelligence play a role?

It is not clear who will be the winner, but the stakes are global and large. Emergency life saving diagnostics can command a premium price in the market. Understand the different drivers of this huge global diagnostic market and find where the opportunities lie.

Our facts and support = Your success.

The report forecasts the market size out for five years. Growth is coming from the basic factors related to improving levels of health care throughout the world. In addition the legacy of the pandemic has changed the playing field for respiratory infections. Some players have already made their mark but disruptive diagnostic technology could change the playing field. Learn about this market including the issues and outlooks. The two key trends of Rapid Diagnostics and the Genomics Revolution are merging to create new diagnostic opportunities.

All report data is available in Excel format on request.

Make investment decisions and valuations with confidence using the latest data.

Table of Contents

1. Market Guides

• 1.1. Situation Analysis
• 1.2. Guide for Executives and Marketing Staff
• 1.3. Guide for Investment Analysts and Management Consultants

2. Introduction and Market Definition

• 2.1. An Overview of Sepsis Diagnostics
  • 2.1.1. Sepsis the medical emergency
  • 2.1.2. Sepsis Diagnosis and Comorbidity
• 2.2. Market Definition
  • 2.2.1. Market Size
  • 2.2.2. Currency
  • 2.2.3. Years
  • 2.2.4. Microbiology
  • 2.2.5. PCR
  • 2.2.6. Immunoassay
  • 2.2.7. Other Infectious Disease
  • 2.2.8. Syndromic PoC
  • 2.2.9. Biomarkers Molecular Diagnostics
  • 2.2.10. Biomarkers Other
  • 2.2.11. Limitations
• 2.3. Methodology
  • 2.3.1. Methodology
  • 2.3.2. Sources
  • 2.3.3. Authors
• 2.4. Perspective: Healthcare and the IVD Industry
  • 2.4.1. Global Healthcare Spending
  • 2.4.2. Spending on Diagnostics
  • 2.4.3. Important Role of Insurance for Diagnostics

3. Sepsis - Current Science

• 3.1. What is Sepsis?
  • 3.1.1. Organ Damage
  • 3.1.2. Neonatal sepsis
  • 3.1.3. Prognosis
• 3.2. Diagnosis
  • 3.2.1. Infection Identification
  • 3.2.2. Biomarkers
  • 3.2.3. Differential diagnosis
  • 3.2.4. The Cytokine Storm - Diagnostic Needs
• 3.3. Causes of Sepsis
  • 3.3.1. Sepsis Progression
  • 3.3.2. The Cytokine Storm - COVID and Other Situations
• 3.4. Prevalence
  • 3.4.1. Impact of COVID on Sepsis Prevalence

4. Industry Overview

• 4.1. Players in a Dynamic Market
  • 4.1.1. Academic Research Lab
  • 4.1.2. Diagnostic Test Developer
  • 4.1.3. Instrumentation Supplier
  • 4.1.4. Chemical/Reagent Supplier
  • 4.1.5. Pathology Supplier
  • 4.1.6. Independent Clinical Laboratory
  • 4.1.7. Public National/regional Laboratory
  • 4.1.8. Hospital Laboratory
  • 4.1.9. Physicians Office Lab (POLS)
  • 4.1.10. Audit Body
  • 4.1.11. Certification Body

5. Market Trends

• 5.1. Factors Driving Growth
  • 5.1.1. Increasing Prevalence
  • 5.1.2. Antimicrobial Resistance
  • 5.1.3. Artificial Intelligence Impact
  • 5.1.4. Multiplex Diagnostics Impacts
  • 5.1.5. The Aging World
  • 5.1.6. Developing World Impact
• 5.2. Factors Limiting Growth
  • 5.2.1. The Cost Curve Shrinks the Market
  • 5.2.2. The Diagnostics Dillemma
  • 5.2.3. Adoption Lag and Cost Control
• 5.3. Instrumentation, Automation and Diagnostic Trends
  • 5.3.1. Traditional Automation and Centralization
  • 5.3.2. The New Automation, Decentralization and Point Of Care
  • 5.3.3. Instruments Key to Market Share
  • 5.3.4. Bioinformatics Plays a Role
  • 5.3.5. PCR Takes Command
  • 5.3.6. Next Generation Sequencing Fuels a Revolution
  • 5.3.7. NGS Impact on Pricing
  • 5.3.8. Whole Genome Sequencing, A Brave New World
  • 5.3.9. Companion Diagnostics Blurs Diagnosis and Treatment
  • 5.3.10. Shifting Role of Diagnostics
  • 5.3.11. The Next Five Years

6. Sepsis Diagnostics - Recent Developments

• 6.1. Recent Developments - Importance and How to Use This Section
  • 6.1.1. Importance of These Developments
  • 6.1.2. How to Use This Section
• 6.2. FDA Clears Abionic's Sepsis Test
• 6.3. MicrosensDx to develop sepsis test
• 6.4. Cytovale's sepsis diagnostic test shows results
• 6.5. Inflammatix Completes Sepsis Test System
• 6.6. Microplate Dx to Launch UTI Susceptibility Test
• 6.7. QC for DiaSorin's Luminex Sepsis Tests Cleared
• 6.8. Cytovale IntelliSep
• 6.9. Prenosis to Study Sepsis in Acute Care
• 6.10. DiaSorin Gains CE Mark for Sepsis Assay
• 6.11. Cytovale to Launch Sepsis Risk-Scoring Test
• 6.12. Todos Medical to Offer Sepsis PCR Test
• 6.13. SeptiCyte-R RAPID Validated
• 6.14. Cepheid Group B Strep Test Addresses Neonatal Sepsis
• 6.15. DeepUll Inks Financing Deal
• 6.16. Sequencing-Based Approach Shows Promise for Sepsis Dx
• 6.17. VolitionRx Studies Cancer, Sepsis Tests
• 6.18. Cytovale Prepping Sepsis Test for FDA Submission
• 6.19. Great North R & I to Develop POC Sepsis Dx
• 6.20. Pathogenomix Developing Sepsis Testing Platform
• 6.21. Gradientech Launches Study of AST System
• 6.22. Sepsis Test Developers Accelerate Plans
• 6.23. Immunexpress Receives Clearance for Sepsis Assay
• 6.24. Prenosis, Roche Partner on Sepsis Detection
• 6.25. Presymptom Health Developing Test for Sepsis
• 6.26. Ortho Clinical Diagnostics Interleukin-6 Reagent Pack
• 6.27. Cytovale to Enter Sepsis Testing Market
• 6.28. Baebies Awarded $11.6M to Develop Diagnostic Platform to ID Sepsis
• 6.29. Personalized Medicine in Sepsis
• 6.30. Point-of-care Device can Diagnose Sepsis in 30 Minutes
• 6.31. SpeeDx Developing Respiratory Virus Host-Response Test
• 6.32. Scanogen Developing Blood Infection Test with Sepsis Application
• 6.33. Inflammatix Developing New Sepsis Dx
• 6.34. Immunexpress, Biocartis to Roll Out Sepsis Test
• 6.35. Sepset Biosciences Using COVID-19 Patient Samples to Validate Sepsis Test
• 6.36. Immunexpress to Develop Sepsis Test
• 6.37. DNAe Developing POC Sequencing for Sepsis
• 6.38. NGS technique offers quick, accurate diagnosis of Sepsis
• 6.39. Portable device diagnoses sepsis faster

7. Profiles of Key Companies

• 7.1. Abbott Laboratories
• 7.2. Abionic
• 7.3. Accel Diagnostics
• 7.4. Accelerate Diagnostics
• 7.5. ADT Biotech
• 7.6. Anatolia Geneworks
• 7.7. Axis-Shield Diagnostics Ltd.
• 7.8. Baebies
• 7.9. Beckman Coulter Diagnostics
• 7.10. Becton, Dickinson and Company
• 7.11. Biocartis
• 7.12. BioFire Diagnostics (bioMerieux)
• 7.13. bioMerieux Diagnostics
• 7.14. Bio-Rad Laboratories, Inc.
• 7.15. Bruker
• 7.16. Cube Dx
• 7.17. Curetis N.V. / Curetis GmbH
• 7.18. Cytovale
• 7.19. Deepull Diagnostics
• 7.20. DNAe
• 7.21. EKF Diagnostics Holdings
• 7.22. GeneFluidics
• 7.23. GenMark Dx (Roche)
• 7.24. Grifols
• 7.25. Immunexpress
• 7.26. Inflammatix
• 7.27. LightDeck Diagnostics
• 7.28. Linear Diagnostics
• 7.29. Luminex Corp (DiaSorin)
• 7.30. Mobidiag (Hologic)
• 7.31. NanoDx
• 7.32. Nanomix
• 7.33. Qiagen
• 7.34. Response Biomedical
• 7.35. Roche Molecular Diagnostics
• 7.36. SeLux Diagnostics
• 7.37. Septec
• 7.38. Siemens Healthineers
• 7.39. Sphingotec
• 7.40. T2 Biosystems
• 7.41. Thermo Fisher Scientific Inc.
• 7.42. Vela Diagnostics

8. Sepsis Global Diagnostic Markets Overview

• 8.1. Sepsis Diagnostics - Global Market Overview by Country
  • 8.1.1. Table - Global Market by Country
  • 8.1.2. Chart - Global Market by Country
• 8.2. Global Sepsis Diagnostics Markets Overview by Assay
  • 8.2.1. Table - Global Market by Assay
  • 8.2.2. Chart - Global Market by Assay - Segments Growth
  • 8.2.3. Chart - Global Market by Assay - Share by Year
  • 8.2.4. Chart - Global Market by Assay
  • 8.2.5. Chart - Global Market by Assay - Base Year
  • 8.2.6. Chart - Global Market by Assay - Final Year
• 8.3. Global Sepsis Diagnostics Markets Overview by Cause
  • 8.3.1. Table - Global Market by Cause
  • 8.3.2. Chart - Global Market by Cause - Segments Growth
  • 8.3.3. Chart - Global Market by Cause - Share by Year
  • 8.3.4. Chart - Global Market by Cause
  • 8.3.5. Chart - Global Market by Cause - Base Year
  • 8.3.6. Chart - Global Market by Cause - Final Year
• 8.4. Global Sepsis Diagnostics Markets Overview by Product
  • 8.4.1. Table - Global Market by Product
  • 8.4.2. Chart - Global Market by Product - Segments Growth
  • 8.4.3. Chart - Global Market by Product - Share by Year
  • 8.4.4. Chart - Global Market by Product
  • 8.4.5. Chart - Global Market by Product - Base Year
  • 8.4.6. Chart - Global Market by Product - Final Year
• 8.5. Global Sepsis Diagnostics Markets Overview by Lab
  • 8.5.1. Table - Global Market by Lab
  • 8.5.2. Chart - Global Market by Lab - Segments Growth
  • 8.5.3. Chart - Global Market by Lab - Share by Year
  • 8.5.4. Chart - Global Market by Lab
  • 8.5.5. Chart - Global Market by Lab - Base Year
  • 8.5.6. Chart - Global Market by Lab - Final Year
• 8.6. Global Sepsis Diagnostics Markets Overview by Place
  • 8.6.1. Table - Global Market by Place
  • 8.6.2. Chart - Global Market by Place - Segments Growth
  • 8.6.3. Chart - Global Market by Place - Share by Year
  • 8.6.4. Chart - Global Market by Place
  • 8.6.5. Chart - Global Market by Place - Base Year
  • 8.6.6. Chart - Global Market by Place - Final Year

9. Sepsis Diagnostic Market - by Assay

• 9.1. Sepsis Diagnostic - Microbiology
  • 9.1.1. Table Sepsis Diagnostic Microbiology - by Country
  • 9.1.2. Chart - Sepsis Diagnostic Microbiology Growth
• 9.2. Sepsis Diagnostic - PCR
  • 9.2.1. Table Sepsis Diagnostic PCR - by Country
  • 9.2.2. Chart - Sepsis Diagnostic PCR Growth
• 9.3. Sepsis Diagnostic - Immunoassay
  • 9.3.1. Table Sepsis Diagnostic Immunoassay - by Country
  • 9.3.2. Chart - Sepsis Diagnostic - Immunoassay Growth
• 9.4. Sepsis Diagnostic - Infectious Disease Other
  • 9.4.1. Table Sepsis Diagnostic Infectious Disease Other - by Country
  • 9.4.2. Chart - Sepsis Diagnostic - Infectious Disease Other Growth
• 9.5. Sepsis Diagnostic - Biomarker MDx
  • 9.5.1. Table Sepsis Diagnostic Biomarker MDx - by Country
  • 9.5.2. Chart - Sepsis Diagnostic - Biomarker MDx Growth
• 9.6. Sepsis Diagnostic - Biomarker Other
  • 9.6.1. Table Sepsis Diagnostic Biomarker Other - by Country
  • 9.6.2. Chart - Sepsis Diagnostic - Biomarker Other Growth

10. Global Sepsis Diagnostics Markets - By Cause

• 10.1. Sepsis Diagnostic - GastroIntestinal
  • 10.1.1. Table Sepsis Diagnostic GastroIntestinal - by Country
  • 10.1.2. Chart - Sepsis Diagnostic GastroIntestinal Growth
• 10.2. Sepsis Diagnostic - Respiratory COVID-19
  • 10.2.1. Table Sepsis Diagnostic Respiratory COVID-19- by Country
  • 10.2.2. Chart - Sepsis Diagnostic Respiratory COVID-19
• 10.3. Sepsis Diagnostic - Respiratory Other
  • 10.3.1. Table Sepsis Diagnostic Respiratory Other - by Country
  • 10.3.2. Chart - Sepsis Diagnostic - Respiratory Other Growth
• 10.4. Sepsis Diagnostic - Neonatal
  • 10.4.1. Table Sepsis Diagnostic Neonatal - by Country
  • 10.4.2. Chart - Sepsis Diagnostic - Neonatal Growth
• 10.5. Sepsis Diagnostic - Other Cause
  • 10.5.1. Table Sepsis Diagnostic Other Cause - by Country
  • 10.5.2. Chart - Sepsis Diagnostic - Other Cause Growth

11. Global Sepsis Diagnostics Markets - By Product

• 11.1. Sepsis Diagnostic - Instrumentation
  • 11.1.1. Table Sepsis Diagnostic Instrumentation - by Country
  • 11.1.2. Chart - Sepsis Diagnostic Instrumentation Growth
• 11.2. Sepsis Diagnostic - Consumables
  • 11.2.1. Table Sepsis Diagnostic Consumables - by Country
  • 11.2.2. Chart - Sepsis Diagnostic Consumables
• 11.3. Sepsis Diagnostic - Software & Service
  • 11.3.1. Table Sepsis Diagnostic Software & Service - by Country
  • 11.3.2. Chart - Sepsis Diagnostic - Software & Service Growth

12. Global Sepsis Diagnostics Markets - By Lab

• 12.1. Sepsis Diagnostic - In Lab
  • 12.1.1. Table Sepsis Diagnostic In Lab - by Country
  • 12.1.2. Chart - Sepsis Diagnostic In Lab Growth
• 12.2. Sepsis Diagnostic - Point of Care
  • 12.2.1. Table Sepsis Diagnostic Point of Care - by Country
  • 12.2.2. Chart - Sepsis Diagnostic Point of Care

13. Global Sepsis Diagnostics Markets - By Place

• 13.1. Sepsis Diagnostic - Hospital
  • 13.1.1. Table Sepsis Diagnostic Hospital - by Country
  • 13.1.2. Chart - Sepsis Diagnostic Hospital Growth
• 13.2. Sepsis Diagnostic - Other Place
  • 13.2.1. Table Sepsis Diagnostic Other Place - by Country
  • 13.2.2. Chart - Sepsis Diagnostic Other Place

14. Appendices

• 14.1. United States Medicare System: Clinical Laboratory Fees Schedule
• 14.2. The Most Used IVD Assays
• 14.3. The Highest Grossing Assays

관련자료